WEKO3
-
RootNode
アイテム
Promotion of Medical R&D in Japan under Abenomics
https://doi.org/10.24545/00001508
https://doi.org/10.24545/000015081f774b38-48b5-4a85-be16-5219d879464d
名前 / ファイル | ライセンス | アクション |
---|---|---|
DP16-11.pdf (206.2 kB)
|
|
Item type | ディスカッションペーパー / Discussion Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-08-18 | |||||
タイトル | ||||||
タイトル | Promotion of Medical R&D in Japan under Abenomics | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Abenomics | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | policy reform | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | health policy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | medical R&D | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | innovation | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_18gh | |||||
資源タイプ | technical report | |||||
ID登録 | ||||||
ID登録 | 10.24545/00001508 | |||||
ID登録タイプ | JaLC | |||||
著者 |
ITO, Yuko
× ITO, Yuko× NAGANO, Hiroshi |
|||||
著者別名 | ||||||
識別子Scheme | WEKO | |||||
識別子 | 8301 | |||||
姓名 | 伊藤, 裕子 | |||||
言語 | ja | |||||
著者別名 | ||||||
識別子Scheme | WEKO | |||||
識別子 | 8302 | |||||
姓名 | 永野, 博 | |||||
言語 | ja | |||||
著者所属 | ||||||
値 | 政策研究大学院大学 / National Graduate Institute for Policy Studies | |||||
著者所属 | ||||||
値 | 慶応義塾大学 / Keio University | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Japan’s cabinet has been pushing forward with economic policy knowns as Abenomics since December 26 in 2012. Abenomics also includes the promotion of R&D in the medical field and related legislative reforms. The Headquarters for Healthcare and Medical Strategy Promotion was established in the cabinet in 2013. In 2014, “Act to Promote Healthcare and Medical Strategy” was promulgated and included for the formulation of the Health and Medical Strategy, the creation of the Plan for Promotion of medical R&D by the Headquarters, and the newly establishment for Japan Agency for Medical Research and Development. In 2014 the Pharmaceutical Affairs Law was revised and it newly contains the strengthening of safety measures for pharmaceuticals and medical devices, the construction of regulations taking into account the characteristics of medical devices, and a new definition for regenerative medicine along with approvals for manufacturing and sales in light of its special characteristics. Further, “Sakigake Package Strategy” formulated in 2014, which included an “advanced review designation system” as a fast-track- applications. With only three years having passed since the implementation of the policies related to Abenomics in 2013, it may be premature to judge their outcome, but several positive signs are appearing. | |||||
発行年 | ||||||
値 | 2016-08 | |||||
書誌情報 |
en : GRIPS Discussion Papers 巻 DP16-11, 発行日 2016-08-18 |
|||||
出版者 | ||||||
出版者 | GRIPS Policy Research Center | |||||
言語 | en | |||||
関連サイト | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | URI | |||||
関連識別子 | https://ideas.repec.org/p/ngi/dpaper/16-11.html | |||||
関連名称 | https://ideas.repec.org/p/ngi/dpaper/16-11.html | |||||
著者情報 | ||||||
内容記述タイプ | Other | |||||
内容記述 | https://www.grips.ac.jp/list/jp/facultyinfo/nagano_hiroshi/ | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa |